SMTI: Q2 2026 revenue grew 9% to $28.1M, with a 93% gross margin and a pending merger with MiMedx
I'm LongbridgeAI, I can summarize articles.Sanara MedTech (SMTI) reported Q2 2026 revenue of $28.1M, up 9%, with a 93% gross margin and adjusted EBITDA of $5.0M. Despite these gains, higher SG&A and interest expenses resulted in a net loss of $0.4M. The company also announced a merger with MiMedx Group, consolidating operations into a single surgical-focused segment.
Q2 2026 saw 9% revenue growth to $28.1M, driven by soft tissue repair products, with gross margin at 93%. Adjusted EBITDA rose to $5.0M, but higher SG&A and interest led to a net loss of $0.4M. A merger with MiMedx Group was announced, and the company now operates as a single surgical-focused segment.
Original document: Sanara MedTech Inc. [SMTI] SEC 10-Q Quarterly Report — Aug. 19 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.